PMID- 31902854 OWN - NLM STAT- MEDLINE DCOM- 20200903 LR - 20200903 IS - 1347-3409 (Electronic) IS - 1345-4676 (Linking) VI - 87 IP - 3 DP - 2020 Jul 13 TI - Intravenous Immunoglobulin Attenuates Cecum Ligation and Puncture-Induced Acute Lung Injury by Inhibiting Apoptosis of Alveolar Epithelial Cells. PG - 129-137 LID - 10.1272/jnms.JNMS.2020_87-303 [doi] AB - PURPOSE: Intravenous immunoglobulin (IVIG) therapy has been used to treat sepsis, but its mechanisms of action remain unclear. Sepsis causes multiple organ failure, such as acute lung injury (ALI), which involves apoptosis of alveolar epithelial cells. In this study, we hypothesized that IVIG suppresses apoptosis in alveolar epithelial cells and evaluated mortality, cytokine levels, histological changes in the lung, and alveolar epithelial cell apoptosis after IVIG administration, in mice with experimentally induced sepsis. METHODS: Mice received an injection of vehicle (saline) or immunoglobulin (100 mg/kg or 400 mg/kg) into the tail vein, after which they underwent cecal ligation and puncture. A sham-operated group was used as the normal control. Survival was assessed in all groups after 72 hours. Plasma levels of TNF-alpha and IL-6, histopathological changes and wet-to-dry ratio in lung, and alveolar epithelial cell apoptosis were evaluated in all groups at 4 hours after surgery. RESULTS: In the vehicle group, histopathological injury of the lung was severe, and apoptosis of alveolar epithelial cells was significant. Survival and plasma cytokine levels were better in the IVIG treatment groups than in the vehicle group. IVIG 400 mg/kg suppressed apoptosis of alveolar epithelial cells and reduced ALI. CONCLUSION: IVIG suppressed inflammatory cytokine levels and improved survival. Lung histopathology and alveolar epithelial cell apoptosis were improved by IVIG treatment, in a dose-dependent manner. Suppressing apoptosis in alveolar epithelial cells appears to be a mechanism by which IVIG improves survival. FAU - Hagiwara, Jun AU - Hagiwara J AD - Department of Emergency and Critical Care Medicine, Graduate School of Medicine, Nippon Medical School. FAU - Yamada, Marina AU - Yamada M AD - Faculty of Medical Science, Nippon Sport Science University. FAU - Motoda, Norio AU - Motoda N AD - Department of Pathology, Nippon Medical School Musashi Kosugi Hospital. FAU - Yokota, Hiroyuki AU - Yokota H AD - Department of Emergency and Critical Care Medicine, Graduate School of Medicine, Nippon Medical School. LA - eng PT - Journal Article DEP - 20191227 PL - Japan TA - J Nippon Med Sch JT - Journal of Nippon Medical School = Nippon Ika Daigaku zasshi JID - 100935589 RN - 0 (Immunoglobulins, Intravenous) RN - 0 (Inflammation Mediators) RN - 0 (Interleukin-6) RN - 0 (Tumor Necrosis Factor-alpha) SB - IM MH - Acute Lung Injury/*drug therapy/*etiology MH - Animals MH - Apoptosis/*drug effects MH - *Cecum MH - Dose-Response Relationship, Drug MH - Immunoglobulins, Intravenous/*administration & dosage/*pharmacology MH - Inflammation Mediators/blood MH - Interleukin-6 MH - Ligation/*adverse effects MH - Male MH - Mice, Inbred C57BL MH - Pulmonary Alveoli/*drug effects/*pathology MH - Punctures/*adverse effects MH - Tumor Necrosis Factor-alpha/blood OTO - NOTNLM OT - animal OT - apoptosis of alveolar epithelial cells OT - intravenous immunoglobulin OT - sepsis EDAT- 2020/01/07 06:00 MHDA- 2020/09/04 06:00 CRDT- 2020/01/07 06:00 PHST- 2020/01/07 06:00 [pubmed] PHST- 2020/09/04 06:00 [medline] PHST- 2020/01/07 06:00 [entrez] AID - 10.1272/jnms.JNMS.2020_87-303 [doi] PST - ppublish SO - J Nippon Med Sch. 2020 Jul 13;87(3):129-137. doi: 10.1272/jnms.JNMS.2020_87-303. Epub 2019 Dec 27.